GOSS Message Board Post 10053280 | Gossamer Bio Inc.
home / stock / goss / goss message board
Andri92
(investorshub)
Posted on: Apr/20/2022 23:43:11
Source: investorshub
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=168609713
Raymond James Initiates Coverage On Gossamer Bio with
News, Short Squeeze, Breakout and More Instantly...
-
2024-06-24 17:15:03 ET Oppenheimer analyst issues OUTPERFORM recommendation for GOSS on June 24, 2024 04:04PM ET. The previous analyst recommendation was Buy. GOSS was trading at $0.8261 at issue of the analyst recommendation. The overall analyst consensus : BUY. Cur...
-
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), will present up...
-
- Transformative Development and Co-Commercialization Collaboration with Chiesi - - Ongoing PROSERA Phase 3 Study in PAH Expected to Readout in Q4 2025 - - Registrational Phase 3 in PH-ILD Expected to Commence in Mid-2025 - - TORREY Phase 2 PAH Results Published in Lancet ...